Montanaro UK Smaller Companies IT Reports Full-Year Results: 'The Light is Darkest Before the Dawn'

Montanaro UK Smaller Companies Investment Trust, better known as MUSCIT, has reported a pretty mixed set of full-year results for the year ended 31 March 2026. The trust’s net asset value, or NAV – the value of its underlying portfolio per share – delivered a total return of just 0.1%, miles behind its benchmark return of 11.9%.

That is the headline problem. But it is not the whole story. The share price total return was better at 3.0%, helped by the discount to NAV narrowing from 8.4% to 6.2%, and shareholders were paid an eye-catching 6.51p across the year in dividends.

Montanaro UK Smaller Companies Investment Trust annual results: key numbers investors need to know

Metric	2026	2025
Share price total return	3.0%	Not disclosed in this table
NAV total return	0.1%	Not disclosed in this table
Benchmark total return	11.9%	Not disclosed in this table
Share price	93.70p	97.00p
NAV per share	99.90p	105.86p
Discount to NAV	6.2%	8.4%
Net assets	£114.6 million	£150.8 million
Dividends per share	6.5p	5.4p
Revenue return per share	3.2p	3.3p
Ongoing charges	1.0%	0.9%

The key takeaway is simple enough: portfolio performance was weak, but shareholder returns were cushioned by a narrowing discount and a generous dividend policy.

Why MUSCIT underperformed the UK smaller companies benchmark so badly

MUSCIT’s manager is blaming a nasty market backdrop for “Quality Growth” investing. In plain English, the trust focuses on higher-quality smaller companies with growth potential, and that style has been badly out of favour.

The company says that over the last 12 months, Quality lagged the broad UK stock market by 17.9%, Growth underperformed Value by 2.1%, and AIM underperformed listed UK small caps by 5.4%. Since MUSCIT leans into all three of those factors, it got hit from several directions at once.

That explanation makes sense, but investors should not let it become a free pass. A trust exists to navigate difficult markets, not just explain them afterwards. A 0.1% NAV return versus an 11.9% benchmark gain is a serious gap.

Still, context matters. Since launch in 1995, MUSCIT says it has delivered a cumulative NAV total return of 811%, ahead of the benchmark’s 651%. So this is a rough period inside a much longer record, not evidence that the whole strategy has permanently broken.

MUSCIT dividend yield, share buybacks and discount: the parts income investors will notice first

The dividend is doing a lot of the heavy lifting here. During the year, the trust paid four quarterly dividends totalling 6.51p, and the board says the quarterly payout is now 1.5% of NAV, equivalent to roughly a 6% annual NAV yield and about a 6.4% share price yield at the current discount.

That is attractive on the face of it, especially in a part of the market where many investors are still looking for reasons to stay interested. But there is an important detail: revenue return per share was only 3.2p, so the dividend was not covered by this year’s income alone.

The board says the company has substantial reserves to continue paying attractive dividends in future. That is helpful, but investors should still keep an eye on it. High yields are great – right up until they are not.

Buybacks were also a big theme. MUSCIT bought back 27,736,173 shares during the year, equal to 19.5% of outstanding shares, and those shares are now held in treasury. That is a chunky number, and it helps explain why the discount narrowed from 8.4% to 6.2%.

For existing shareholders, that is a positive. A narrower discount means the share price held up better than the portfolio itself. The flip side is that gross assets fell to £124.6 million and net assets dropped to £114.6 million, so the trust is smaller than it was a year ago.

Portfolio changes show Montanaro is not sitting still

One encouraging part of the update is that the manager has clearly been active. The portfolio was reshaped to reduce risk and improve diversification, with the number of holdings rising from 40 to 59.

That also reduced concentration. The top 10 investments fell from around 41% of the portfolio a year ago to around 32% now. In a volatile market, that is a sensible move.

There were several new positions, including Craneware, Restore, FRP Advisory, Renew Holdings, SRT Marine Systems and Filtronic. The manager also says the trust participated in the Beauty Tech Group flotation, which has already seen earnings forecasts upgraded four times at the time of writing.

Portfolio turnover rose to 60.2% from 45.6%, which tells you this was not a minor tidy-up. The trust is now described as less benchmark-sensitive and less volatile, with a beta of 0.92 and tracking error of 5.5%.

That sounds sensible, although investors should remember the simple truth: defensive repositioning is only useful if it eventually feeds through into better relative returns.

Best and worst holdings in the MUSCIT portfolio

The biggest positive contributors were XP Power, JTC and Alpha Group. The latter two benefited from takeover interest, with JTC receiving an offer from Permira at around a 50% premium and Alpha Group seeing an approach from Corpay at around a 55% premium.

On the downside, Hilton Foods, Bytes Technology and XPS Pensions were the main detractors. So the portfolio had some winners, but not enough to offset the wider style headwinds and weaker areas of the market.

MUSCIT AGM, continuation vote and governance changes: why they matter

This annual results statement is also tied to an important AGM on 29 July 2026. Shareholders will be asked to back a continuation resolution that would remove the requirement for a wind-up vote in 2027 and allow the trust to continue for another five years.

The board is strongly in favour, and it points out that more than 99% of shareholders supported continuation in 2021. There are also proposed changes to the articles of association to improve transparency around any investment manager appointment where conflicts of interest may exist, and to deal with the unlikely event that the board falls below three directors.

That governance detail may sound dry, but it matters. In the investment trust world, alignment and shareholder protections are not small print – they are part of the investment case.

What these Montanaro UK Smaller Companies results mean for retail investors

My view is that this is a results set with a clear split personality. On one hand, the core performance number is disappointing and there is no dressing that up. MUSCIT badly lagged both versions of its benchmark over one year, and the five-year numbers are weak too.

On the other hand, the trust is doing several things right for shareholders. It is buying back stock aggressively, keeping the discount in single digits, paying a high quarterly dividend, cutting the management fee basis to net assets rather than gross assets, and actively repositioning the portfolio.

So, is this one to avoid or one to watch? I would say it is one to watch closely. If you believe UK smaller companies are cheap and due a recovery, MUSCIT offers geared exposure – gearing means borrowing to invest more – plus a hefty income stream while you wait.

But if you want proof that the turnaround has already arrived, these numbers do not give it to you yet. The manager is asking investors to look through a miserable style cycle and focus on history, valuations and future earnings growth. That may prove right, but for now it still requires patience.

For retail investors, that is the real verdict. MUSCIT looks interesting, shareholder-friendly and potentially well placed for a recovery in UK small caps – but it still needs to turn that story into stronger benchmark performance.